Oramed Pharmaceuticals In... (ORMP)
Oramed Pharmaceuticals Inc. (ORMP) Stock Price, Analysis & Data
| Bid | 3.4 |
| Market Cap | 198M |
| Revenue (ttm) | n/a |
| Net Income (ttm) | 174.06M |
| Beta | 1.16 |
| EPS (ttm) | 4.13 |
| PE Ratio (ttm) | 1.15 |
| Forward PE | -59.5 |
| P/B (ttm) | 0.62 |
| P/S (ttm) | n/a |
| Earnings Date | Nov 12, 2026 |
| Ask | 5.78 |
| Volume | 297,698 |
| Avg. Volume (20D) | 292,669 |
| Open | 4.56 |
| Previous Close | 4.57 |
| Day's Range | 4.48 - 4.82 |
| 52-Week Range | 2.05 - 5.19 |
| Analyst | n/a |
| Price Target | n/a |
| Dividends | $0.25 (5.22%) |
| Ex-Dividend Date | Jan 16, 2026 |
About ORMP
Oramed Pharmaceuticals Inc. engages in the research and development of pharmaceutical solutions with a technology platform for the oral delivery of therapeutic proteins. It develops ORMD-0801, an oral insulin capsule, which is in phase III clinical trial for the treatment of individuals with diabetes. The company has license agreements with Oravax Medical Inc. to commercialize oral vaccines for COVID-19. Oramed Pharmaceuticals Inc. was incorporat...
Financial Performance
In 2025, Oramed Pharmaceuticals's revenue was 2M, an increase of undefined% compared to the previous year's 0. Earnings were 64.05M, a decrease of -436.04%.
Financial StatementsEarnings Surprise
Analysts project revenue of ... Upgrade
3 months ago · Simply Wall St.
Spotlight On Oramed Pharmaceuticals And Two Other Prominent Penny StocksThe market has climbed 1.5% in the last 7 days and is up 26% over the last 12 months, with earnings forecast to grow by 17% annually. While the term 'penny stock' might seem outdated, these investment...
